AU2020302839B2 - Novel molecules - Google Patents

Novel molecules

Info

Publication number
AU2020302839B2
AU2020302839B2 AU2020302839A AU2020302839A AU2020302839B2 AU 2020302839 B2 AU2020302839 B2 AU 2020302839B2 AU 2020302839 A AU2020302839 A AU 2020302839A AU 2020302839 A AU2020302839 A AU 2020302839A AU 2020302839 B2 AU2020302839 B2 AU 2020302839B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
prodrug
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020302839A
Other languages
English (en)
Other versions
AU2020302839A1 (en
Inventor
Christophe Demaison
Ian Holmes
David Jackson
Grant MCLACHLAN
Weiguang Zeng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENA Respiratory Pty Ltd
Original Assignee
ENA Respiratory Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902231A external-priority patent/AU2019902231A0/en
Application filed by ENA Respiratory Pty Ltd filed Critical ENA Respiratory Pty Ltd
Publication of AU2020302839A1 publication Critical patent/AU2020302839A1/en
Assigned to Ena Respiratory Pty Ltd reassignment Ena Respiratory Pty Ltd Request for Assignment Assignors: Axelia Oncology Pty Ltd
Application granted granted Critical
Publication of AU2020302839B2 publication Critical patent/AU2020302839B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
    • C07C321/14—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3348—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2020302839A 2019-06-26 2020-06-26 Novel molecules Active AU2020302839B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2019902231A AU2019902231A0 (en) 2019-06-26 Novel molecules
AU2019902231 2019-06-26
AU2019904862 2019-12-20
AU2019904862A AU2019904862A0 (en) 2019-12-20 Novel molecules (2)
PCT/AU2020/050660 WO2020257870A1 (en) 2019-06-26 2020-06-26 Novel molecules

Publications (2)

Publication Number Publication Date
AU2020302839A1 AU2020302839A1 (en) 2022-01-20
AU2020302839B2 true AU2020302839B2 (en) 2025-08-14

Family

ID=74059610

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020302839A Active AU2020302839B2 (en) 2019-06-26 2020-06-26 Novel molecules

Country Status (12)

Country Link
US (2) US20220388950A1 (https=)
EP (1) EP3990428A4 (https=)
JP (2) JP2022539091A (https=)
KR (1) KR20220050873A (https=)
CN (2) CN121045535A (https=)
AU (1) AU2020302839B2 (https=)
BR (1) BR112021025630A8 (https=)
CA (1) CA3142501A1 (https=)
IL (1) IL289266B1 (https=)
MX (1) MX2021015961A (https=)
NZ (1) NZ783377A (https=)
WO (1) WO2020257870A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2618842T3 (da) 2010-09-22 2019-07-01 Ena Therapeutics Pty Ltd Hidtil ukendt immunstimulerende fremgangsmåde
EP3728289B1 (en) 2017-12-21 2025-09-10 Axelia Oncology Pty Ltd Optimised compounds
KR20220050873A (ko) 2019-06-26 2022-04-25 악셀리아 온콜로지 피티와이 리미티드 신규한 분자
EP4157255A4 (en) * 2020-05-26 2024-07-03 Ena Respiratory Pty Ltd CORONAVIRUS TREATMENT
WO2021258154A1 (en) 2020-06-26 2021-12-30 Axelia Oncology Pty Ltd Branched lipid compounds
EP4395762A1 (en) * 2021-09-02 2024-07-10 Ena Respiratory Pty Ltd Formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119759A1 (en) * 2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2018176099A1 (en) * 2017-03-31 2018-10-04 Ena Therapeutics Pty Ltd Treatment of respiratory infection with a tlr2 agonist
WO2019043604A1 (en) * 2017-08-30 2019-03-07 Auckland Uniservices Limited PEPTIDE CONJUGATES, CONJUGATION METHOD, AND USES THEREOF

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1239876B1 (en) 1999-11-19 2008-07-30 Csl Limited Hcv vaccine compositions
EP2000144A1 (en) 2000-05-19 2008-12-10 Corixa Corporation Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono-and disaccharide-based compounds
EP1382352A1 (de) 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein-Konjugate und deren Verwendung
BR0313101A (pt) 2002-08-12 2005-06-28 Queensland Inst Med Res Novos lipopeptìdeos imunogênicos que compreendem epitopos de linfócitos t-helper e linfócitos t citotóxicos (ctl), e métodos para sua produção e uso
EP2301972A1 (en) 2002-08-12 2011-03-30 The Council Of The Queensland Institute Of Medical Research Method to prepare immunogenic lipopeptides comprising T-helper and B-cell epitopes
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
US20060002941A1 (en) 2004-01-23 2006-01-05 Vievax Corp. Compositions comprising immune response altering agents and methods of use
WO2005079419A2 (en) 2004-02-17 2005-09-01 The Regents Of The University Of California Methods of treating immunopathological disorders
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
CN102614510A (zh) 2004-10-18 2012-08-01 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
EP1666056A1 (en) 2004-12-06 2006-06-07 Bestewil Holding B.V. Cancer vaccine vesicles
NZ556004A (en) 2004-12-21 2010-05-28 Vaxinnate Corp Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein
BRPI0607605A2 (pt) 2005-02-08 2009-09-15 Queensland Inst Med Res moléculas imunogênicas
AU2006216822A1 (en) 2005-02-22 2006-08-31 Daniel Rachmilewitz Methods of treating gastrointestinal inflammation
EP1787660A1 (en) * 2005-11-22 2007-05-23 GBF Gesellschaft für Biotechnologische Forschung mbH New adjuvants on the basis of bisacyloxypropylcysteine conjugates and their uses in pharmaceutical compositions
US20070224205A1 (en) 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2008085549A2 (en) 2006-07-28 2008-07-17 Board Of Regents Of The University Of Texas System Compositions and methods for stimulation of lung innate immunity
AU2014202674B2 (en) * 2007-05-04 2014-08-14 Marina Biotech, Inc. Amino acid lipids and uses thereof
EP2200638B1 (en) 2007-10-09 2016-03-16 The University of Melbourne Compositions for the transfection of cells
WO2009137103A2 (en) 2008-05-09 2009-11-12 Ourth Donald D Anti-cancer/anti-viral compounds and methods of use
WO2009155332A1 (en) 2008-06-17 2009-12-23 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
EP2334332A4 (en) 2008-09-05 2013-01-09 Id Biomedical Corp Quebec NEW COMPOSITIONS AND NEW ADJUVANTS
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
ES2534947T3 (es) 2009-03-25 2015-04-30 The Board Of Regents Of The University Of Texas System Composiciones para la estimulación de resistencia inmunitaria innata de mamíferos a patógenos
WO2010115229A1 (en) 2009-04-09 2010-10-14 The University Of Melbourne Immunogenic composition and uses thereof
GB0907989D0 (en) 2009-05-08 2009-06-24 Hybrid Systems Ltd Multivalent adjuvant display
EP2338521A1 (en) 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
DK2618842T3 (da) 2010-09-22 2019-07-01 Ena Therapeutics Pty Ltd Hidtil ukendt immunstimulerende fremgangsmåde
JP6240077B2 (ja) * 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
WO2014207708A2 (en) 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
WO2016037240A1 (en) 2014-09-12 2016-03-17 The University Of Melbourne Immunological reagent
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
JP2016216593A (ja) 2015-05-19 2016-12-22 株式会社リコー 反応材、熱交換器及びケミカルヒートポンプ
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3419962A4 (en) 2016-02-26 2020-03-11 Auckland Uniservices Limited CONJUGATES OF AMINO ACIDS AND PEPTIDES AND CONJUGATION METHOD
NL2018803B1 (en) * 2017-04-27 2018-11-05 Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc Adjuvant compounds
US20210177795A1 (en) 2017-12-21 2021-06-17 Ena Therapeutics Pty Ltd Administering compounds
EP3728289B1 (en) * 2017-12-21 2025-09-10 Axelia Oncology Pty Ltd Optimised compounds
KR20220050873A (ko) * 2019-06-26 2022-04-25 악셀리아 온콜로지 피티와이 리미티드 신규한 분자
US20220347146A1 (en) 2019-09-04 2022-11-03 Axelia Oncology Pty Ltd Cancer treatment
WO2021042171A1 (en) 2019-09-04 2021-03-11 Ena Therapeutics Pty Ltd Cancer immunotherapy
EP4157255A4 (en) 2020-05-26 2024-07-03 Ena Respiratory Pty Ltd CORONAVIRUS TREATMENT

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119759A1 (en) * 2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2018176099A1 (en) * 2017-03-31 2018-10-04 Ena Therapeutics Pty Ltd Treatment of respiratory infection with a tlr2 agonist
WO2019043604A1 (en) * 2017-08-30 2019-03-07 Auckland Uniservices Limited PEPTIDE CONJUGATES, CONJUGATION METHOD, AND USES THEREOF

Also Published As

Publication number Publication date
NZ783377A (en) 2026-03-27
CN114174260B (zh) 2025-09-05
EP3990428A1 (en) 2022-05-04
CN121045535A (zh) 2025-12-02
BR112021025630A8 (pt) 2023-04-11
EP3990428A4 (en) 2023-07-19
JP2025108536A (ja) 2025-07-23
US20220388950A1 (en) 2022-12-08
CA3142501A1 (en) 2020-12-30
US12017979B2 (en) 2024-06-25
BR112021025630A2 (pt) 2022-02-15
MX2021015961A (es) 2022-03-22
AU2020302839A1 (en) 2022-01-20
WO2020257870A1 (en) 2020-12-30
IL289266B1 (en) 2026-03-01
IL289266A (en) 2022-02-01
JP2022539091A (ja) 2022-09-07
CN114174260A (zh) 2022-03-11
KR20220050873A (ko) 2022-04-25
US20230257345A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
AU2020302839B2 (en) Novel molecules
EP3728289B1 (en) Optimised compounds
AU2021278377A1 (en) Treatment of coronavirus
EP4172142B1 (en) Branched lipid compounds
US20210177795A1 (en) Administering compounds
US20140288312A1 (en) Compounds for the treatment of influenza
EA051455B1 (ru) Новые молекулы
US20250302972A1 (en) Formulation
ES2911027T3 (es) Compuestos para aplicaciones medicinales

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ENA RESPIRATORY PTY LTD

Free format text: FORMER APPLICANT(S): AXELIA ONCOLOGY PTY LTD

FGA Letters patent sealed or granted (standard patent)